Evidence map›Paper›PMID 40578909›Full record

ArticleJournal of the American Board of Family Medicine : JABFM

The Unintentional Detection of Leukemias with Complete Blood Count.

Yung Gonzaga, Felipe Nogueira Barbara, Luis C L Correia, Arn Migowski

Abstract read
In one paragraph

Article in Journal of the American Board of Family Medicine : JABFM. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Women's Health Care, Prevention in Practice, and Common Medical Illnesses.Journal of the American Board of Family Medicine : JABFM
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yung GonzagaFrom the Department of Hematology, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil (YG); Grupo Oncoclínicas, Rio de Janeiro, Brazil (YG); Independent Researcher (FNB); Rollins School of Public Health, Emory University, Atlanta, GA (LCLC); Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil (LCLC); Clinical Research and Technological Development Divison, Research and Innovation Coordination, Instituto Nacional de Câncer (INCA), Ministry of Health, Rio de Janeiro, Brazil (AM); Professional Master's Program in Health Technology Assessment, Teaching and Research Coordination, Instituto Nacional de Cardiologia (INC), Rio de Janeiro, Brazil (AM). ygonzaga@inca.gov.br).
Felipe Nogueira BarbaraFrom the Department of Hematology, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil (YG); Grupo Oncoclínicas, Rio de Janeiro, Brazil (YG); Independent Researcher (FNB); Rollins School of Public Health, Emory University, Atlanta, GA (LCLC); Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil (LCLC); Clinical Research and Technological Development Divison, Research and Innovation Coordination, Instituto Nacional de Câncer (INCA), Ministry of Health, Rio de Janeiro, Brazil (AM); Professional Master's Program in Health Technology Assessment, Teaching and Research Coordination, Instituto Nacional de Cardiologia (INC), Rio de Janeiro, Brazil (AM).
Luis C L CorreiaFrom the Department of Hematology, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil (YG); Grupo Oncoclínicas, Rio de Janeiro, Brazil (YG); Independent Researcher (FNB); Rollins School of Public Health, Emory University, Atlanta, GA (LCLC); Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil (LCLC); Clinical Research and Technological Development Divison, Research and Innovation Coordination, Instituto Nacional de Câncer (INCA), Ministry of Health, Rio de Janeiro, Brazil (AM); Professional Master's Program in Health Technology Assessment, Teaching and Research Coordination, Instituto Nacional de Cardiologia (INC), Rio de Janeiro, Brazil (AM).
Arn MigowskiFrom the Department of Hematology, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil (YG); Grupo Oncoclínicas, Rio de Janeiro, Brazil (YG); Independent Researcher (FNB); Rollins School of Public Health, Emory University, Atlanta, GA (LCLC); Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil (LCLC); Clinical Research and Technological Development Divison, Research and Innovation Coordination, Instituto Nacional de Câncer (INCA), Ministry of Health, Rio de Janeiro, Brazil (AM); Professional Master's Program in Health Technology Assessment, Teaching and Research Coordination, Instituto Nacional de Cardiologia (INC), Rio de Janeiro, Brazil (AM).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The complete blood count (CBC) is the most requested medical test in the world and it is used for various clinical purposes. Due to its characteristic of quantifying red blood cells, white blood cells, and platelets, it assesses bone marrow function, where most leukemias originate. Therefore, the test has the potential to unintentionally detect different types of leukemia. Screening refers to the application of a diagnostic test to a population without signs or symptoms of the disease. Although the request of a CBC in clinical practice does not necessarily constitute screening, the premise that early detection allows more effective treatment, preventing deaths and allowing patients to live longer, may also apply to leukemias. In this article, leukemias and the CBC are used as a didactic platform to explain some aspects regarding potential benefits, harms, and limitations of incidental detection of diseases in asymptomatic individuals and its implications for the primary care clinician.

Indexed as

Incidental FindingsLeukemiaBlood Cell CountEarly Detection of CancerHumansCancerComplete Blood CountDiagnostic TestsHematologyIncidental FindingsLeukemiaOvertreatmentPrimary Health CareScreening

Identifiers

PMID40578909
PMCPMC12616821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.